63 related articles for article (PubMed ID: 18701330)
1. Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study-determination of immunogenicity.
Lenders M; Brand E
J Med Genet; 2024 May; 61(6):531-533. PubMed ID: 38538083
[No Abstract] [Full Text] [Related]
2. Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study - determination of immunogenicity.
Warnock DG; Wallace EL
J Med Genet; 2024 May; 61(6):534-535. PubMed ID: 38589225
[No Abstract] [Full Text] [Related]
3. Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
Pisani A; Riccio E; Sabbatini M
Genet Med; 2015 Jan; 17(1):21-3. PubMed ID: 25010055
[No Abstract] [Full Text] [Related]
4. Agalsidase alfa and kidney dysfunction in Fabry disease.
West M; Nicholls K; Mehta A; Clarke JT; Steiner R; Beck M; Barshop BA; Rhead W; Mensah R; Ries M; Schiffmann R
J Am Soc Nephrol; 2009 May; 20(5):1132-9. PubMed ID: 19357250
[TBL] [Abstract][Full Text] [Related]
5. Case report of concurrent Fabry disease and amyotrophic lateral sclerosis supports a common pathway of pathogenesis.
Beer AM; Cooper-Knock J; Fletcher S; Brown-Wright SH; Nandakumar TP; Shaw PJ
Amyotroph Lateral Scler Frontotemporal Degener; 2016; 17(7-8):614-616. PubMed ID: 27094629
[No Abstract] [Full Text] [Related]
6. Spastic quadriparesis in Fabry disease: A diagnostic challenge.
Jha S; Vengalil S; Ravindranadh CM; Nalini A; Yadav R
Natl Med J India; 2023; 36(5):340-341. PubMed ID: 38759977
[No Abstract] [Full Text] [Related]
7. Fabry disease: A pharmacological chaperone on the horizon.
Gaggl M; Sunder-Plassmann G
Nat Rev Nephrol; 2016 Nov; 12(11):653-654. PubMed ID: 27665929
[No Abstract] [Full Text] [Related]
8. Fabry disease, enzyme replacement therapy and the significance of antibody responses.
Deegan PB
J Inherit Metab Dis; 2012 Mar; 35(2):227-43. PubMed ID: 22037707
[TBL] [Abstract][Full Text] [Related]
9. Fabry disease.
Germain DP
Orphanet J Rare Dis; 2010 Nov; 5():30. PubMed ID: 21092187
[TBL] [Abstract][Full Text] [Related]
10. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.
Hsu J; Serrano D; Bhowmick T; Kumar K; Shen Y; Kuo YC; Garnacho C; Muro S
J Control Release; 2011 Feb; 149(3):323-31. PubMed ID: 21047542
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.
Fervenza FC; Torra R; Warnock DG
Biologics; 2008 Dec; 2(4):823-43. PubMed ID: 19707461
[TBL] [Abstract][Full Text] [Related]
12. Medical bioremediation of age-related diseases.
Mathieu JM; Schloendorn J; Rittmann BE; Alvarez PJ
Microb Cell Fact; 2009 Apr; 8():21. PubMed ID: 19358742
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease in children and the effects of enzyme replacement treatment.
Pintos-Morell G; Beck M
Eur J Pediatr; 2009 Nov; 168(11):1355-63. PubMed ID: 19242721
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
[No Abstract] [Full Text] [Related]
15. Treatment with agalsidase beta during pregnancy in Fabry disease.
Politei JM
J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
[TBL] [Abstract][Full Text] [Related]
16. Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.
Senocak Tasci E; Bicik Z
Iran J Kidney Dis; 2015 Sep; 9(5):406-8. PubMed ID: 26338166
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease.
Kalkum G; Macchiella D; Reinke J; Kölbl H; Beck M
Eur J Obstet Gynecol Reprod Biol; 2009 May; 144(1):92-3. PubMed ID: 19233535
[No Abstract] [Full Text] [Related]
18. Agalsidase alfa: specific treatment for Fabry disease.
Mehta A
Hosp Med; 2002 Jun; 63(6):347-50. PubMed ID: 12096664
[TBL] [Abstract][Full Text] [Related]
19. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
Morel CF; Clarke JT
Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
